Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
ASPEN
Introduction
Click here to download slides for ASPEN.
Overview
Overview
In 1905 patients with diabetes and no prior CHD, the composite/primary end-point and secondary end-points of CV mortality, fatal/non-fatal MI, revascularizations, strokes or hospitalization for angina were similar in the treatment group (atorvastatin 10 mg daily) and placebo[1].
References
References
- ↑ Knopp RH, d’Emden M, Smilde JG, Pocock SJ (2006). “Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)”. Diabetes Care. 29 (7): 1478–85. doi:10.2337/dc05-2415. PMID 16801565. Review in: ACP J Club. 2006 Nov-Dec;145(3):62
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]